MetaVia (MTVA) Non-Current Debt (2017 - 2018)
MetaVia's (MTVA) quarterly Non-Current Debt came in at $6.4 million in Q3 2018, down 35.79% YoY from $10.0 million in Q3 2017, and down 15.15% on a QoQ basis from $7.5 million in Q2 2018.
MetaVia (MTVA) Non-Current Debt (2017 - 2018) Analysis & Trends
MetaVia (MTVA) has 2 years of Non-Current Debt data on file, last reported at $6.4 million in Q3 2018.
- Quarterly Non-Current Debt fell 35.79% year-over-year to $6.4 million in Q3 2018, while the trailing twelve-month figure through Sep 2018 was $6.4 million (down 35.79% YoY) and the FY2017 annual result came in at $8.7 million, changed N/A from the prior year.
- Non-Current Debt slipped to $6.4 million in Q3 2018, from $7.5 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $10.0 million in Q3 2017 to a low of $6.4 million in Q3 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 8.96 Bn |
| 10 | MetaVia | 8.72 Mn | -3.92 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 6.40 Mn |
| Jun 30, 2018 | 7.54 Mn |
| Mar 31, 2018 | 7.76 Mn |
| Dec 31, 2017 | 8.68 Mn |
| Sep 30, 2017 | 9.96 Mn |